Topic: How To Invest

Power Growth Investor Hotline – Friday, January 17, 2025

Article Excerpt

ELI LILLY AND COMPANY, $725.72, is a buy. The drugmaker (symbol LLY on New York) discovers, develops, manufactures and markets human pharmaceutical products. The company expects to report revenue of $45.0 billion for 2024, which is 32% above its 2023 revenue. However, that prediction is below the consensus forecast of $45.3 billion due to slower-than-expected sales for its Zepbound and Mounjaro weight loss drugs. However, sales of Zepbound should improve now that the Food and Drug Administration has approved it as a treatment for obstructive sleep apnea. As a result, the U.S. Medicare insurance plan will cover the costs of this drug. Lilly is also planning to launch Zepbound in other countries, including China, India and Latin America. For 2025, the company now sees its overall revenue rising to between $58 billion and $61 billion. The midpoint of that range—$59.5 billion—is above the consensus estimate of $58.5 billion. Eli Lilly is a buy. Eli Lilly recent coverage: January 2025 Issue Hotline for December 20, 2024 RESTAURANT…